

UddfcUWzA YEfc[fUa a YEa cghEYUWYXZhgAj YFU YE
 [cUAf]b[AYfghfYUa Ybhci bXh' 1 LAbXKXgE
]bAh YEgWbXh' *1 E'AbAh YEi Uhm mEfYUa YbhE
 UddfcUWzA YE+AE][\ df]cf]hAa a i b]hYgAf[YhXE
 Xi f]b[AYfghEhXgYWbXhEi UhmfgEZRSS&A YhA YE
 [cUAmEW]j]b[A)1 AbXh'1 Aj YU YzEgYm]j YmE
 Si f]b[AYgWbXhEUEZRSS&ASAX]hcbUAfchUzEhE
 \][\ df]cf]hAa a i b]hYgE YfYh[YhXZcfEi Uhm mE
 hYUa YbhZcj YFU YEUGYggE WggZ zEW]j]b[A)1 A
 UbXE, 1 Aj YFU YAbA YhA]fXAbXhEi fhEi Uhm gE
 respectively.

bU hfgEi]Aj UYbhEfbfUWfAYE SS&Aci fbYgAZUWgKYhU
 hA YbhBUBgEYAMfYhE AfU]hA YbhGya Ygf]YzEUAj Yh fyE
 VWYEAfYgei YhfEh]bh h UAgY h h

Serological assessments in the Yanomami Focus Area from 2018 to 2022

Gfc`c[]WAEgYga Yb]gEYAWbXh WXhE]hA YE@G5AE
 Cj %AU]bcg]hWg'

Venezuela South Focus

-bR&S&ZfY]a]b]fmiEg hgZca Efc`c[]WAEg]b[EZE
 &S&AM] XfYbA] YXh - AUfg]bA EZE% Aa a i b]hYg]bE
 ' A] VUFYgEYUfA Yb]U]]UbAcfXfA] ckYXh UhE`AE
 hcgyAghXhE YfYg]fcbY] Uj YhTable 1). The results
 cZfEgYga Yb]g]bA) Aa a i b]hYg]bEh YfA] VUFYgE
]bR&S&A] `AVYdfYg]b]Xh]b]b]c] Ya VfR&S&A]hE YE
 -bhf5a Y]WbA]cbZfYbWAc]bWcWVU]g]hE57CLE
 a Yh]b]b]Ei U]a UU'

Brazil Amazonas Focus

Gfc`c[]WAEgYga Yb]gEYAWbXh WXh]bR&S%ì &S&E
]bA] S&AM] XfYbA] YXh - AUfg]bA EZEh YE% A] VUFYgE
]bAYZcWg]Table 2). Preliminary results showed an

1 Preliminary results of Ov16 serological assessments in children aged 1–9 years in 3 subareas of the Venezuela South Focus (May–July 2022)

Table 1. Résultats préliminaires des évaluations sérologiques Ov16 chez les enfants âgés de 1-9 ans dans 3 sous-zones du foyer sud du Venezuela (mai-juillet 2022)

Subarea or sector – Sous-zone ou secteur	No. of children aged 1–5 years assessed – Nbre d'enfants âgés de 1-5 ans testés	No. of positive samples in children aged 1–5 years – Nbre d'échantillons positifs chez les enfants âgés de 1-5 ans	Prevalence in children aged 1–5 years (%) – Prévalence chez les enfants âgés de 1-5 ans (%)	No. of children aged 6–9 years assessed – Nbre d'enfants âgés de 6-9 ans testés	No. of positive samples in children aged 6–9 years – Nbre d'échantillons positifs chez les enfants âgés de 6-9 ans	Prevalence in children aged 6–9 years (%) – Prévalence chez les enfants âgés de 6-9 ans (%)	Total no. of children assessed – Nbre total d'enfants testés	Total no. of positive samples – Nbre total d'échantillons positifs	Total prevalence (%) – Prévalence totale (%)	No. of treatment rounds with 85% coverage – Nbre de tournées de traitement avec une couverture 85%
At. Cal-a / Ka. qáa ٢٠٠	18	0	0.0	22	0	0.0	40	0	0.0	10
At. Cal-a / ٨ ٤ ٢٠٠	35	0	0.0	25	0	0.0	60	0	0.0	14
٨ ٢٠٠ / Cal ١ ٢٠٠	38	0	0.0	20	0	0.0	58	0	0.0	6
٨ ٢٠٠ / At ٨ ٢٠٠	19	0	0.0	11	0	0.0	30	0	0.0	11
Ua ad / Ua ad	20	0	0.0	4	0	0.0	24	0	0.0	14
Total no. of samples processed – Nbre total d'échantillons analysés	130	0	0.0	82	0	0.0	212	0	0.0	

2 Preliminary results of Ov16 serological assessment of children aged 1–9 years in 19 subareas of the Brazil Amazonas Focus, 2018–2022

5.2 Résultats préliminaires des évaluations sérologiques Ov16 chez les enfants âgés de 1-9 ans dans 19 sous-zones du foyer de l'Amazonas au Brésil, 2018-2022

Subarea or sector – Sous-zone ou secteur	No. of children aged 1–5 years assessed – Nbre d'enfants âgés de 1-5 ans testés	No. of positive samples in children aged 1–5 years – Nbre d'échantillons positifs chez les enfants âgés de 1-5 ans	Prevalence in children aged 1–5 years (%) – Prévalence chez les enfants âgés de 1-5 ans (%)	No. of children aged 6–9 years assessed – Nbre d'enfants âgés de 6-9 ans testés	No. of positive samples in children aged 6–9 years – Nbre d'échantillons positifs chez les enfants âgés de 6-9 ans	Prevalence in children aged 6–9 years (%) – Prévalence chez les enfants âgés de 6-9 ans (%)	Total no. of children assessed – Nbre total d'enfants testés	Total no. of positive samples – Nbre total d'échantillons positifs	Total prevalence (%) – Prévalence totale (%)	No. of treatment rounds with 85% coverage – Nbre de tournées de traitement avec une couverture 85%
Alta...	424	7	1.7	285	19	6.7	709	26	3.7	21
S...	349	5	1.4	282	13	4.6	631	18	2.9	19
Xe...	203	2	1.0	162	8	4.9	365	10	2.7	36
H...	24	0	0.0	18	1	5.6	42	1	2.4	31
A.d...	85	2	2.4	53	1	1.9	138	3	2.2	28
Ha...	82	0	0.0	61	3	4.9	143	3	2.1	36
Ba.a...	73	0	0.0	44	1	2.3	117	1	0.9	43
Ha...	161	2	1.2	109	0	0.0	270	2	0.7	37
T t t b...	58	0	0.0	15	0	0.0	73	0	0.0	48
At. Pa...	32	0	0.0	18	0	0.0	50	0	0.0	21
At. Ca...	13	0	0.0	5	0	0.0	18	0	0.0	38
Ka a...	8	0	0.0	5	0	0.0	13	0	0.0	25
N B...	83	0	0.0	28	0	0.0	111	0	0.0	38
Wa...	37	0	0.0	23	0	0.0	60	0	0.0	29
Pa...	23	0	0.0	24	0	0.0	47	0	0.0	38
Pa.a...	2	0	0.0	3	0	0.0	5	0	0.0	40
Ma...ca Pa...	18	0	0.0	15	0	0.0	33	0	0.0	35
Wa...	31	0	0.0	17	0	0.0	48	0	0.0	33
Sa-ba	18	0	0.0	11	0	0.0	29	0	0.0	25
Total no. of samples processed – Nbre total d'échantillons analysés	1724	18	1.0	1178	46	3.9	2902	64	2.2	

Table 2. Preliminary results of Ov16 serological assessment of children aged 1–9 years in 19 subareas of the Brazil Amazonas Focus, 2018–2022

Editorial note

The elimination of onchocerciasis, included intercommunity transmission, is a major public health goal in the Amazon region. This report provides preliminary results of the serological assessment of children aged 1–9 years in 19 subareas of the Brazil Amazonas Focus, 2018–2022. The overall prevalence of Ov16 antibodies was 2.2%, indicating that the elimination of onchocerciasis is still a major public health goal in the Amazon region.

